Insys Therapeutics Reaffirms Second Quarter 2014 Revenue Guidance
PHOENIX, AZ -- (Marketwired) -- 06/30/14 -- Insys Therapeutics, Inc. (INSY) today reaffirmed its revenue guidance for the second quarter ended June 30, 2014. Revenue from sales of Subsys® (Fentanyl Sublingual Spray) is expected to exceed $52.0 million for the quarter, as compared with $18.5 million during the second quarter of 2013.
The company plans to release its unaudited financial results for the second quarter ended June 30, 2014 before the U.S. financial markets open on Tuesday, August 12, 2014.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using its proprietary sublingual spray technology and its capability to develop pharmaceutical cannabinoids, the company addresses the clinical shortcomings of existing commercial products. The company currently markets two products, Subsys, which is sublingual Fentanyl spray for break through cancer pain, and a generic version of Dronabinol (THC) capsules. The company plans to file a New Drug Application (NDA) for an oral liquid formulation of Dronabinol in the second half of 2014 and believes it is a clinically superior product to current Dronabinol capsules. The company is developing a pipeline of sublingual sprays, as well as pharmaceutical CBD.
This press release contains forward-looking statements, including statements regarding anticipated net revenue for the second quarter of 2014, plans of the company to file an NDA for oral liquid formulation of Dronabinol in the second half of 2014 and the development of pipeline of sublingual sprays, as well as pharmaceutical CBD. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
Contact: Lisa M. Wilson President In-Site Communications, Inc. 212-452-2793
Source: Insys Therapeutics